PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7300529

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MEDERI THERAPEUTICS, INC.	04/24/2018

RECEIVING PARTY DATA

Name:	HORIZON CREDIT II LLC
Street Address:	312 FARMINGTON AVENUE
City:	FARMINGTON
State/Country:	CONNECTICUT
Postal Code:	06032

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16510899

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 12033290289

Email: ndgershon@gmail.com **Correspondent Name: NEIL D. GERSHON** Address Line 1: 1200 HIGH RIDGE ROAD

Address Line 4: STAMFORD, CONNECTICUT 06905

ATTORNEY DOCKET NUMBER:	8132 DIV CON
NAME OF SUBMITTER:	NEIL D. GERSHON
SIGNATURE:	/Neil D. Gershon Reg. #32,225/
DATE SIGNED:	04/27/2022

Total Attachments: 13

source=8132DIVCON Assignment Horizon Credit To Mederi RF FINAL#page1.tif source=8132DIVCON Assignment Horizon Credit To Mederi RF FINAL#page2.tif source=8132DIVCON Assignment Horizon Credit To Mederi RF FINAL#page3.tif source=8132DIVCON Assignment Horizon Credit To Mederi RF FINAL#page4.tif source=8132DIVCON Assignment Horizon Credit To Mederi RF FINAL#page5.tif source=8132DIVCON Assignment Horizon Credit To Mederi RF FINAL#page6.tif

source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page7.tif
source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page8.tif
source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page9.tif
source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page10.tif
source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page11.tif
source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page12.tif
source=8132DIVCON_Assignment_Horizon_Credit_To_Mederi_RF_FINAL#page13.tif

[Execution Version]

ASSIGNMENT OF PATENTS

WHEREAS, Mederi Therapeutics Inc., a Delaware corporation ("<u>Debtor</u>"), with its principal place of business located at 800 Connecticut Avenue, Suite 1E01, Norwalk, CT 06854, is the owner of the entire right, title and interest in and to the Patents and Patent Applications (as defined below);

WHEREAS, Debtor is indebted to Horizon Credit II LLC, a Delaware limited liability company ("Lender"), which holds security interests in substantially all of Debtor's personal property, including the Patents and Patent Applications;

WHEREAS, Debtor granted to Lender a security interest in all of Debtor's right, title, and interest in and to the Patents and Patent Applications, pursuant to (a) the Venture Loan and Security Agreement, dated as of December 20, 2013, as amended by the (i) First Amendment of Venture Loan and Security Agreement, dated as of July 23, 2015, and (ii) Second Amendment of Venture Loan and Security Agreement, dated as of January 30, 2017 (as amended, restated, supplemented, and/or modified from time to time, the "Loan Agreement") and (b) the Grant of Security Interest (Patents), dated as of July 30, 2015, made by Debtor in favor of Lender, which was recorded at the United States Patent and Trademark Office on August 3, 2015, at Reel/Frame 036252/0728;

WHEREAS, Debtor is currently in default of its obligations to Lender pursuant to the terms of the Loan Agreement;

WHEREAS, Lender is entitled to exercise its remedies under the Loan Documents (as defined in the Loan Agreement) and applicable law, including the Uniform Commercial Code as presently enacted in the State of Connecticut (including, to the extent applicable to the transactions contemplated herein, the Uniform Commercial Code as enacted in any other state, the "Code"; terms used herein and defined in Section 42a-9-101 of the Code shall have the meanings ascribed to such terms therein);

WHEREAS, Lender has sold the Patents and Patent Applications and certain other assets (collectively, the "<u>Transferred Assets</u>") by private foreclosure sale (the "<u>Foreclosure Sale</u>") to Mederi RF, LLC, a Delaware limited liability company, having a principal place of business at 114 Holmes Road, Suite 201, Houston, Texas 77405 ("<u>Purchaser</u>") by and pursuant to that certain Secured Party Bill of Sale and Transfer Statement, dated as of April 24, 2018, by and among Lender and Purchaser (the "<u>Bill of Sale</u>"); and

WHEREAS, capitalized terms used but not defined herein shall have meanings given them in the Bill of Sale.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the purchase price paid by Purchaser, the receipt and sufficiency of which is hereby acknowledged, Lender, through the Foreclosure Sale, does hereby sell, assign, transfer and set over unto Purchaser, its successors and assigns, Debtor's entire right, title and interest in and to all patents and patent applications of Debtor, including without limitation those listed on Schedule A hereto, and any continuation, divisional, continuations-in-

part, reissues, extensions, re-examinations or substitutions relating thereto, and any foreign applications based in whole thereon or claiming the benefit thereof; and any United States or foreign patents issued on any of the foregoing; all file histories and physical and electronic documentation, including, without limitation, all invention disclosures, prosecution papers, notes, drawings, reports, flow charts, instructions, manuals, notebooks and memoranda, that directly relate to such patents or patent applications (the foregoing, collectively, the "Patents and Patent Applications"), the same to be held and enjoyed by Purchaser for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, to the end of the term or terms for which said patents are or may be granted or reissued, as fully and entirely as the same would have been held and enjoyed by Debtor, if this assignment and sale had not been made; together with all rights, credits, judgments, choses in action, rights of set-off and any and all other claims of every type and nature of, for or arising from or relating to past, present or future infringement or claims for royalties, and any and all other rights to enforce or protect any rights constituting or relating to any of the Patents and Patent Applications, claims for damages by reason of past, present or future infringement of said patents or for past, present or future royalties or other compensation for such use, with the right to sue for such damages, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives:

AND, Lender does hereby authorize and request competent authorities to issue any Letters Patent as shall be granted upon said patent applications to Purchaser and its successors and assigns.

The Transferred Assets are being sold "as is and where is" and Lender makes no, and hereby disclaims any, representation or warranty to Purchaser with respect to the Transferred Assets or the transactions contemplated hereby, including without limitation any warranty of merchantability or fitness for a particular purpose, and there is no warranty relating to title, possession, quiet enjoyment, or the like which by operation of law would otherwise accompany a voluntary disposition of the Transferred Assets. Without limiting the generality of the foregoing, Lender makes no representation or warranty, express or implied, as to the validity or utility of the Transferred Assets, title to the Transferred Assets, whether the sale will be free and clear of liens and security interests (other than the security interests of Lender), the status of any issued patents or registered trademarks or any applications for patents or trademarks, whether transfer documentation executed by Lender is sufficient to transfer title to Intellectual Property registered in foreign jurisdictions, whether the Intellectual Property or any use thereof infringes on the rights of others, whether any intent-to-use trademark applications are assignable, or whether any license agreements and other contracts are assignable. Further, there is no warranty as to the existence, location or condition of any tangible assets constituting Transferred Assets. Certain molds, inventory, and other tangible Transferred Assets of Debtor may by held by or under the control of third parties, and Lender makes no, and disclaims any, representation or warranty of any kind as to the title to, lien priority with respect to, or the accessibility of such Transferred Assets.

[The remainder of this page is intentionally left blank.]

20124120 4

IN WITNESS WHEREOF, Lender has caused this instrument to be executed by its duly authorized officer as of this 24th day of April, 2018.

LENDER: HORIZON CREDIT II LLC

Mane: Robert D. Pomeroy, Jr.

Title: Chief Executive Officer

State of Connecticit
Country of Herbard) se Farmington

On this 24th day of April, 2018, before me appeared Robert D. Pomeroy, Jr. to me personally known who, being duly sworn, did depose and say that he is the Chief Executive Officer of HORIZON CREDIT II LLC, a Delaware limited liability company, which is named in and which executed the foregoing instrument; and that said instrument was signed on behalf of said corporate entity; and said Robert D. Pomeroy, Ir. acknowledged said instrument to be the

free and authorized act and deed of each of said corporate entity.

Notary Public / Commission Expires.

Tabic Son less State of Sourch A.

REEL: 059728 FRAME: 0662

The undersigned hereby acknowledges the transfer of all of Debtor's rights in the Transferred Assets pursuant to Section 42a-9-617 of the Code and consents and agrees to the assignment and conveyance of the Patents and Patent Applications pursuant to this Assignment of Patents.

IN WITNESS WHEREOF, Debtor has caused this instrument to be executed by its duly authorized officer as of this 24th day of April, 2018.

DEBTOR: MEDERITHERAPEUTICS INC.

ly: ("

Vame: John Andros

Title: Chief Financial Officer

State of CT County of FOLIC FIR No.

iss Lionrue

On this 3 day of April, 2018, before me appeared John Andros, to me personally known who, being duly sworn, did depose and say that he is the Chief Financial Officer of MEDERI THERAPEUTICS INC., the Delaware corporation named in and which executed the foregoing instrument; and that said instrument was signed on behalf of said Delaware corporation; and said John Andros acknowledged said instrument to be the free and authorized act and deed of said Delaware corporation.

Notary Public

My Commission Expires:

Commission Express
And 30, 2022

REEL: 059728 FRAME: 0663

SCHEDULE A

PATENTS AND PATENT APPLICATIONS

[SEE ATTACHED]

Docket	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
PENDING-U.S.				
8078 DIV4 CON	Fecal incontinence	U.S.	14/828,320	8/17/15
8082DIVCON2	Fecal incontinence	U.S.	14/953,202	11/27/15
8103 DIV3CON	ID code	U.S.	14/866,632	9/25/15
8110 DIV2 CON	Arm lumens; Irrigation manifold	U.S.	14/214,872	04/22/14
8122CONDIV3 CON	Sensing pressure	U.S.	15/669,866	8/4/17
8123DIVCON2	Use with endoscope	U.S.	15/462,838	3/18/17
8130CONIICON	GUI2	U.S.		
8130CONVI	GUI2	US.	15/261,932 15/068,539	9/10/16 3/12/16
	GC12	03	13/008,339	3/12/10
8130CIPDIV	Non-Ablation	U.S.	15/268,574	9/17/16
8130CIPII	GUI2:	US	15/436,827	2/19/17
8131DIV	Spacer	U.S.	15/607,301	5/26/17
8132DIV	Electrode Alignment	U.S,	15/675,584	8/11/17
8134CON	Suction Disabling	U.S.	15/713,591	9/22/17
8135	Endoscope sheath	U.S.	14/866,664	9/25/15
ISSUED-U.S.		1 0.0.	1 17/000,007	17/23/13
8036 CONDIV 4	Curi	1	Tara tara a sa	
8030 CONDIV 4	GUI 1	U.S.	12/001,091	12/10/07
00040055555			8,906,010	12/9/14
8036CONDIV4 CON	GUI 1	U.S.	14/556,199	11/30/14
			9.844,406	12/19/17
8041CONDIV2	Arm Lumens	U.S.	14/523,856	10/25/14
CON 2			9,539,052	1/10/17
8043 DIV 3 CON	Spine	U.S.	13/858,061	04/7/13
	formation		8,888,774	11/18/14
8047 DIV	Treatment agent	U.S.	11/079,697	03/14/05
			7,449,020	11/11/08
8047 DIV 2	Treatment agent	U.S.	12/291,626	11/12/08
			8,518,032	08/27/13
8053 CON 3 DIV CON	Energy delivery	U.S.	12/653,018	12/07/09
			8,454,595	06/04/13
8074CON	Energy delivery	U.S.	10/155,294	5/24/02
	3, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	- 1-1	6,712,074	3/30/04
8078	Anal canal treatment	U.S.	09/556,169	04/21/00
		0.0.	6,645,201	11/11/03
8078 DIV	Anal canal treatment	U.S.	10/674.242	09/29/03
		0.0.	7,056,320	06/06/06
8078 DIV 2	Fecal incontinence	U.S.	11/446,771	06/05/06
55.521.2	1 dour modulinence	0.0.	7,699,844	04/20/10
8078 DIV 3	Fecal incontinence	U.S.	12/799.169	04/20/10
70.022,0	1 Cour modulmence	0.5.	8,597,290	12/03/13
8078 DIV 4	Fecal incontinence	U.S.	14/055,077	10/16/13
3070 D1 V -7	1 cent incommence	0.3.	9,125,665	9/8/15
8080	Treatment agent	U.S.	09/994.375	11/26/01
8080	Treatment agent	U.S.	1	
8080 DIV	Treatment agent	TIC	6,790,207	09/14/04
8080 DI V	r reament agent	U.S.	10/912,268	08/05/04
8080 DIV 2	Terestation	II.C	7,293,563	11/13/07
8080 DI V 2	Treatment agent	U.S.	11/906,457	10/02/07
0001		11.0	8,161,976	04/24/12
8081	Treatment agent	U.S.	09/994,379	11/26/01
0001 DIM		716	6.802,841	10/12/04
8081 DIV	Treatment agent	U.S.	10/912,329	08/05/04
0000	<u> </u>		7,458,378	12/02/08
8082	Anal canal treatment	U.S.	10/911,395	08/04/04
0000 BT/ CC.	1		7,329,254	02/12/08
8082 DIV CON	Fecal incontinence	U.S.	14/214,880	3/15/14
			9,204,926	12/8/15
8090	Multiple balloons	U.S.	09/285,575	04/02/99
	_1		6,409,723	06/25/02

Docket	Technology	Country	Serial No. /Patent No	. Filing/Issue Date
8092	ID code	U.S.	10/212,311	08/05/02
			6,783,523	08/31/04
8092 DIV CON	ID code	U.S.	11/895,205	08/23/07
			8,257,346	09/04/12
8092 DIV CON 2	ID code	U.S.	13/590,027	8/20/12
200.000			9.198,705	12/1/15
8095 CON	ID code	U.S.	09/974,750	10/10/01
			6,827,713	12/07/04
8095 CON DIV	ID code	U.S.	10/974,454	10/27/04
8095 CON DIV 2	ID I-	11.0	7,465,301	12/16/08
8095 CON DIV 2	ID code	U.S.	12/315,890	12/08/08
8095 CON DIV	ID code	U.S.	8,449,529 13/892,212	05/28/13 5/10/13
2 CON	ID code	0.3.	9,186,223	11/17/15
8095 CON DIV 2	ID code	U.S.	14/474,16	8/31/14
CON 2	ID code	0.3.	9,750,559	9/5/17
8100	ID code	U.S.	09/574,704	05/18/00
		0.0.	6,464,689	10/15/02
8100 DIV	ID code	U.S.	10/219,798	08/15/02
			6,994,704	02/07/06
8100 DIV 2	ID code	U.S.	11/299,955	12/12/05
			7,922,715	04/12/11
8100 DIV 2 CON	ID code	U.S.	13/084,973	04/12/11
			8,845.632	9/30/14
8100 DIV 2 CON 2	ID code	U.S.	14/492,046	10/16/13
			9,675,404	6/13/17
8101	Use with endoscope	U.S.	09/524,432	03/13/00
			6,544,226	04/08/03
8103	Enabling operation	U.S.	10/070,465	09/07/00
			6,733,495	05/11/04
8103 DIV 3	ID code	U.S.	12/927,353	11/12/10
			9,155,583	10/13/15
8105 CON DIV CON	Obesity treatment	U.S.	13/114,146	05/24/11
0110			8,740,894	06/03/14
8110	Spine formation	U.S.	09/955,915	09/19/01
8110 DIV		TT C	6,699,243	03/02/04
8110 DIV	Irrigation manifold	U.S.	10/760,433	01/20/04
8110 DIV 2	Irrigation manifold	U.S.	7,179,257 11/702.695	02/20/07
0110 DIV 2	migation mannoid	0.8.	8,696,660	02/06/07 04/15/14
8111 DIVCON 3	Spine lumens	U.S.	13/656,714	10/21/12
offi Diveon 3	Spine futtions	0.3.	8,647,298	02/11/14
8111 DIVCON 4	Arm lumens	U.S.	14/158,843	1/19/14
		0.0.	9,675,409	6/13/17
8112 CON	Basket band	U.S.	11/055.450	02/09/05
			7,615,049	11/10/09
8120 CON	Guidewire lumen	U.S.	11/366,650	03/02/06
			7,731,684	06/08/10
8120 CON DIV	Guidewire lumen	U.S.	12/802,324	06/04/10
			8,439,866	05/14/13
8120 CONDIV CON	Guidewire lumen	U.S.	13/854,662	4/1/13
0.10.1			9,107,674	8/18/15
8121	Hemorrhoid treatment	U.S.	10/653,448	09/02/03
ALOL DILL			7,160,294	0.1/09/07
8121 DIV	Hemorrhoid treatment	U.S.	11/650,079	01/05/07
9122 CON	 	- , , , 	8,211,101	07/03/12
8122 CON	Device positioning	U.S.	11/114,592	04/26/05
9133		 	7,422,587	09/09/08
8123	Basket assembly	U.S.	11/055,450 7,615,049	2/9/05
				11/10/09

Docket	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
8123 DIV	Spine lumens	U.S.	12/590,239	11/04/09
			8,728,074	05/20/14
8123 DIVCON	Use with endoscope	U.S.	14/256,979	4/20/14
			9,737,360	8/22/17
8124 CON	Rack & pinion	U.S.	12/287,404	10/09/08
			8.758,340	06/24/14
8130 CON 1	GUI 2	U.S.	13/646,683	10/6/12
			9,310,956	4/12/16
8130 CON II	GUI 2	U.S.	13/651,436	10/14/12
			9,448,681	9/20/16
8130 CONIII	GUI 2	U.S.	13/646.681	10/6/12
			9,292,152	3/22/16
8130 CON IV	GUI 2	U.S.	13/726,155	12/23/12
			9,495,059	11/15/16
8130CONV	GUI2	U.S.	14/953,214	11/27/15
			9,513,761	12/6/16
8130 CIP	Non-Ablation	U.S.	13/867,042	4/20/13
			9,474,565	10/25/16
8131	Spacer	U.S.	14/708,209	5/9/15
			9,675,404	6/13/17
8132	Electrode alignment	U.S.	14/708,210	5/9/15
			9,750,563	9/5/17
8134	Suction Disabling	U.S.	14/839,905	8/25/15
		0.5.	9,775,664	10/3/17
	Method to treat gastric reflux via	U.S.	11/230,801	9/20/05
	the detection and ablation of	0.0.	7,585,296	9/8/09
	gastro-esophageal nerves and		7,505,250	7/0/07
	receptors			
	GERD treatment apparatus and	U.S	11/254,951	10/20/05
	method	0.0	8,313,484	11/20/12
FOREIGN			0,510,404	11/20/12
8039 EP	Advanceable	EP	00000227.2 (105(102)	And the second s
	electrodes	LIF	99908327.2 (1056403)	02/19/99
8039 JA	Advanceable	JA	2000 522065	05/10/00
0.000	electrodes	JA	2000-532065	02/19/99
8071 EP	Generator & pump	EP	(3.879,055)	210.0 (0.0)
() () () () () () () () () ()	Generator & paintp	EF	00930371	5/02/00
8078 EP	Anal canal treatment	EP	1180992	
8078 JA	Anal canal treatment		1196106	1/30/02
8095EP	ID Code	JA	4518008	1/15/02
8130 PCT		EP	00961593.1	09/01/00
0130 PC 1				
0120 ON	GUI 2	PCT	US2010/002588	09/22/10
	GUI 2	CN	US2010/ 002588 2010/ 80052854.4	5/22/12
			US2010/002588	5/22/12 4/17/15
8130CNDIV	GUI 2 GUI2	CN CN	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9	5/22/12
8130CNDIV 8130 EP	GUI 2 GUI 2 GUI 2	CN CN EP	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3	5/22/12 4/17/15
8130CNDIV 8130 EP	GUI 2 GUI2	CN CN	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861	5/22/12 4/17/15 11/14/17
	GUI 2 GUI2 GUI 2 GUI 2	CN CN EP JA	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564	5/22/12 4/17/15 11/14/17 08/22/10
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation	CN CN EP JA	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation	CN CN EP JA	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation	CN CN EP JA	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPCN	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation	CN CN EP JA PCT EP CN	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPEN 8130CIPIPCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation	CN CN EP JA PCT EP CN PCT	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1 PCT/US17/ 23107	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17 3/26/17
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPEN 8130CIPIPCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation GUI 2 Spacer /alignment	CN CN EP JA PCT EP CN PCT PCT	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPCN 8130CIPIPCT 8131PCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation GUI2 Spacer /alignment Spacer/alignment	CN CN EP JA PCT EP CN PCT	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1 PCT/US17/ 23107	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17 3/26/17
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPCN 8130CIPIPCT 8131PCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation GUI2 Spacer /alignment Spacer/alignment Systems for treating	CN CN EP JA PCT EP CN PCT PCT	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1 PCT/US17/ 23107 2015//031660	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17 3/26/17 5/20/15 12/28/16
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPEN 8130CIPIPCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation GUI2 Spacer /alignment Spacer/alignment	CN CN EP JA PCT EP CN PCT PCT PCT EP	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1 PCT/US17/ 23107 2015//031660 15726484.7	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17 3/26/17 5/20/15
8130CNDIV	GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation GUI 2 Spacer /alignment Spacer/alignment Systems for treating malfunctions of the diges and the rectum	CN CN EP JA PCT EP CN PCT PCT PCT EP	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1 PCT/US17/ 23107 2015//031660 15726484.7 60043064	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17 3/26/17 5/20/15 12/28/16 7/6/00
8130CNDIV 8130 EP 8130 JA 8130 CIP PCT 8130CIPEP 8130CIPEN 8130CIPIPCT	GUI 2 GUI 2 GUI 2 GUI 2 Non-ablation Non-ablation Non-ablation GUI2 Spacer /alignment Spacer/alignment Systems for treating malfunctions of the diges and	CN CN EP JA PCT EP CN PCT PCT PCT EP	US2010/ 002588 2010/ 80052854.4 2015/ 10182248.9 10819150.3 2012-530861 5764564 PCT/US13/ 44864 13735092.2 201380044544.1 PCT/US17/ 23107 2015//031660 15726484.7 60043064	5/22/12 4/17/15 11/14/17 08/22/10 3/22/12 6/9/15 6/9/13 1/5/15 2/26/15 2/22/17 3/26/17 5/20/15 12/28/16 7/6/00

3

Docket	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
	Operative devices that can be removable fitted on catheter bodies to treat tissue regions in the body	EP	01920233	3/7/01
	System for treating obesity	EP	03770558	9/26/03
	System for treating obesity and other gastrointestinal conditions	EP	09075210 2095786	9/26/03 6/27/12

4

67907326_3

Docket	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
ISSUED-U.S.				
	MEDICAL INSTRUMENTS AND TECHNIQUES FOR TREATMENT OF URINARY INCONTINENCE	US	08/920,291 5,957,920	08-28-1997 09-28-1999
	MEDICAL INSTRUMEMTS AND TECHNIQUES FOR TREATMENT OF GASTRO - ESOPHAGEAL REFLUX DISEASE	US	09/258,006 6,197,022	02-25-1999 03-06-2001
	CONTROL SYSTEMS FOR MULTIPLE ELECTRODE ARRAYS TO CREATE LESIONS IN TISSUE REGIONS AT OR NEAR A SPHINCTER	US	09/304,733 6,355,031	05-04-1999 03-12-2002
	VACUUM-ASSISTED SYSTEMS AND METHODS FOR TREATING SPHINCTERS AND ADJOINING TISSUE REGIONS	US	09/304,743 6,325,798	05-04-1999 12-04-2001
	SYSTEMS AND METHODS FOR FORMING COMPOSITE LESIONS TO TREAT DYSFUNCTION IN SPHINCTERS AND ADJOINING TISSUE REGIONS	US	09/304,750 6,402,744	05-04-1999 06-11-2002
	ASSEMBLIES TO VISUALIZE AND TREAT SPHINCTERS AND ADJOINING TISSUE REGIONS	US	09/304,770 6,423.058	05-04-1999 07-23-2002
	EXPANDABLE ELECTRODE ASSEMBLIES FOR FORMING LESIONS TO TREAT DYSFUNCTION IN SPHINCTERS AND ADJOINING TISSUE REGIONS	US	09/304,773 6,258,087	05-04-1999 07-10-2001
	ACTIVELY COOLED ELECTRODE ASSEMBLIES FOR FORMING LESIONS TO TREAT DYSFUNCTION IN SPHINCTERS AND ADJOINING TISSUE REGIONS	US	09/304,784 6,440,128	05-04-1999 08-27-2002
	INTEGRATED TISSUE HEATING AND COOLING APPARATUS	US	09/305,079 6.273,886	05-04-1999 08-14-2001
	GRAPHICAL USER INTERFACE FOR ASSOCIATION WITH AN ELECTRODE STRUCTURE DEPLOYED IN CONTACT WITH A TISSUE REGION	US	09/305,123 6,358,245	05-04-1999 03-19-2002
	SPHINCTER TREATMENT APPARATUS	US	09/776,140 6,673,070	02-02-2001 01-06-2004

5

Docket	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
ISSUED-U.S.				
	APPARATUS TO TREAT	US	09/921,356	08-02-2001
	ESOPHAGEAL SPHINCTERS		6,613,047	09-02-2003
	APPARATUS TO TREAT	US	09/971,085	10-04-2001
	ESOPHAGEAL SPHINCTERS		6,749,607	06-15-2004
	GRAPHICAL USER INTERFACE FOR ASSOCIATION WITH AN ELECTRODE STRUCTURE DEPLOYED IN CONTACT WITH A TISSUE REGION	US	10/024,747 7,122,031	12-19-2001 10-17-2006
	ELECTRODES FOR CREATING LESIONS IN TISSUE REGIONS AT OR NEAR A SPHINCTER	US	10/046,637 6,562,034	01-14-2002 05-13-2003
	METHOD TO TREAT GASTRIC REFLUX VIA THE DETECTION AND ABLATION OF GASTRO-ESOPHAGEAL NERVES AND RECEPTORS	US	10/156,505 6,974,456	05-28-2002 12-13-2005
	MEDICAL INSTRUMENTS AND TECHNIQUES FOR TREATMENT OF GASTRO- ESOPHAGEAL REFLUX DISEASE	US	10/375,505 7,167.758	02-27-2003 01-23-2007
	SPHINCTER TREATMENT METHOD	US	10/428,458 6,971,395	05-02-2003 12-06-2005
	SYSTEMS AND METHODS FOR TREATING DYSFUNCTIONS IN THE INTESTINES AND RECTUM THAT ADAPT TO THE ANATOMIC FORM AND STRUCTURE OF DIFFERENT INDIVIDUALS	US	12/004,189 8,696,661	12-20-2007 04-15-2014
	METHOD TO TREAT GASTRIC REFLUX VIA THE DETECTION AND ABLATION OF GASTRO-ESOPHAGEAL NERVES AND RECEPTORS	us	12/584,509 8,870,862	09-08-2009 10-28-2014
	APPARATUS TO DETECT AND TREAT ABERRANT MYOELECTRIC ACTIVITY	US	13/443,503 8,790,339	04-10-2012 07-29-2014
	SURGICAL INSTRUMENTS AND TECHNIQUES FOR TREATING GASTRO- ESOPHAGEAL REFLUX DISEASE	US	13/691,822 8,556,952	12-02-2012 10-15-2013
	SPHINCTER TREATMENT APPARATUS	US	13/902,830 9,351,787	05-26-2013 05-31-2016
	SPHINCTER TREATMENT	US	14/015,993	08-30-2013
	APPARATUS		8,894,646	11-25-2014

	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
ABANDONED/EXP	British January (1990) Arroom (1990) January (1990)			
	SURGICAL INSTRUMENTS FOR TREATING GASTRO- ESPHAGEAL REFLUX	US	09/222,501 6,740,082	12-29-1998 05-25-2004
	MEDICAL INSTRUMENTS AND TECHNIQUES FOR TREATMENT OF GASTRO- ESOPHAGEAL REFLUX DISEASE	US	09/648,345 6.535,768	08-25-2000 03-18-2003
	RF ELECTRODE ARRAY FOR LOW-RATE COLLAGEN SHRINKAGE IN CAPSULAR SHIFT PROCEDURES AND METHODS OF USE	US	10/141,273 6,689,129	05-08-2002 02-10-2004
	SURGICAL INSTRUMENTS AND TECHNIQUES FOR TREATING GASTRO- ESOPHAGEAL REFLUX DISEASE	US	10/780,027 7,008,419	02-17-2004 03-07-2006
	SURGICAL WEIGHT CONTROL DEVICE	US	11/043,902 7,326,207	01-26-2005 02-05-2008
	RF ELECTRODE ARRAY FOR LOW-RATE COLLAGEN SHRINKAGE IN CAPSULAR SHIFT PROCEDURES AND METHODS OF USE	US	11/650,887 7,585,297	01-08-2007 09-08-2009
	MEDICAL INSTRUMENTS AND TECHNIQUES FOR TREATMENT OF GASTRO- ESOPHAGEAL REFLUX DISEASE	US	11/656,062 8,095.222	01-22-2007 01-10-2012
	SYSTEMS AND METHODS FOR TREATING OBESITY AND OTHER GASTROINTESTINAL CONDITIONS	US	13/679,785	11-16-2012
	GERD TREATMENT APPARATUS AND METHOD	US	13/958,542 08-03-2013	
	SYSTEM FOR TREATING GASTRIC REFLUX BY TIGHTENING A LOWER ESOPHAGEAL SPHINCTER	US	14/511,497	10-10-2014
	DEVICE FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE	US	14/536,592	11-08-2014
	SYSTEMS AND METHODS FOR TREATING TISSUE REGIONS OF THE BODY	US	14/588,858	01-02-2015
-	SYSTEMS AND METHODS	US	61/664,960	06-27-2012

Docket	Technology	Country	Serial No. /Patent No.	Filing/Issue Date
ABANDONED/EXPIRED-U.S.				
	FOR CONTROLLING USE AND OPERATION OF A FAMILY OF DIFFERENT TREATMENT DEVICES			
	SYSTEMS AND METHODS FOR TREATING TISSUE WITH RADIOFREQUENCY ENERGY	US	62/009,222	06-07-2014
	SYSTEMS AND METHODS FOR TREATING TISSUE WITH RADIOFREQUENCY ENERGY	US	62/009,223	06-07-2014
	SYSTEMS AND METHODS FOR TREATING TISSUE WITH RADIOFREQUENCY ENERGY	US	62/050,090	09-13-2014
	SYSTEMS AND METHODS FOR TREATING TISSUE WITH RADIOFREQUENCY ENERGY	US	62/065,658	10-18-2014
	SYSTEMS AND METHODS FOR TREATING TISSUE WITH RADIOFREQUENCY ENERGY	US	62/313,710	03-26-2016

PATENT REEL: 059728 FRAME: 0672

RECORDED: 04/27/2022